相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
C. Louwrens Braal et al.
DRUGS (2021)
The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action
Rong Chen et al.
BLOOD CANCER JOURNAL (2021)
Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas
Jing Wu et al.
CLINICAL CANCER RESEARCH (2021)
Current FDA-Approved Therapies for High-Grade Malignant Gliomas
Jacob P. Fisher et al.
BIOMEDICINES (2021)
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors
Andre Richters et al.
CELL CHEMICAL BIOLOGY (2021)
Alternative approaches to target Myc for cancer treatment
Chen Wang et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)
Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy
Aisha Alsfouk
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)
CDK9 inhibitors reactivate p53 by downregulating iASPP
Jiale Wu et al.
CELLULAR SIGNALLING (2020)
Interferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02
Birthe Lohmann et al.
ONCOLOGY LETTERS (2020)
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
Christin Riess et al.
FRONTIERS IN IMMUNOLOGY (2020)
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update
Tizhi Wu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Targeting CDK9: A novel biomarker in the treatment of endometrial cancer
Shasha He et al.
ONCOLOGY REPORTS (2020)
Sensitivity of human meningioma cells to the cyclin-dependent kinase inhibitor, TG02
Caroline von Achenbach et al.
TRANSLATIONAL ONCOLOGY (2020)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2020)
Cyclin-dependent kinase inhibitors in brain cancer: current state and future directions
Viktorija Juric et al.
CANCER DRUG RESISTANCE (2020)
Glioblastoma Stem cells: Driving Resilience through Chaos
Briana C. Prager et al.
TRENDS IN CANCER (2020)
Immunotherapy in CNS cancers: the role of immune cell trafficking
Nivedita M. Ratnam et al.
NEURO-ONCOLOGY (2019)
Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer
Neil Portman et al.
ENDOCRINE-RELATED CANCER (2019)
Challenges to curing primary brain tumours
Kenneth Aldape et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
Karishma R. Rajani et al.
FRONTIERS IN ONCOLOGY (2019)
Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer
Navid Sobhani et al.
CELLS (2019)
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
Jian-Fang Ning et al.
NATURE COMMUNICATIONS (2019)
A Dual Inhibitor of Cdc7/Cdk9 Potently Suppresses T Cell Activation
Elijah W. Chen et al.
FRONTIERS IN IMMUNOLOGY (2019)
Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy
Heyu Song et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2019)
Profound, durable and MGMT-independent sensitivity of glioblastoma cells to cyclin-dependent kinase inhibition
Emilie Le Rhun et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Targeting regulation of cyclin dependent kinase 9 as a novel therapeutic strategy in synovial sarcoma
Xiaoyang Li et al.
JOURNAL OF ORTHOPAEDIC RESEARCH (2019)
Cyclin-dependent kinase 9 (CDK9) is a novel prognostic marker and therapeutic target in osteosarcoma
Hangzhan Ma et al.
EBIOMEDICINE (2019)
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
Marc Hafner et al.
CELL CHEMICAL BIOLOGY (2019)
T-cell Dysfunction in Glioblastoma: Applying a New Framework
Karolina I. Woroniecka et al.
CLINICAL CANCER RESEARCH (2018)
Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Dewan Md Sakib Hossain et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent
Steven T. Sizemore et al.
MOLECULAR CANCER RESEARCH (2018)
Silencing LDHA inhibits proliferation, induces apoptosis and increases chemosensitivity to temozolomide in glioma cells
Hui Di et al.
ONCOLOGY LETTERS (2018)
Human endogenous retroviruses and their implication for immunotherapeutics of cancer
A. S. Attermann et al.
ANNALS OF ONCOLOGY (2018)
Targeting transcription-associated CDKs is an effective way to combat glioblastoma and medulloblastoma with minimal effect on primary neurons
Isha Bhutada et al.
CANCER RESEARCH (2018)
Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma
Jennie W. Taylor et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Primary brain tumours in adults
Sarah Lapointe et al.
LANCET (2018)
Structure of activated transcription complex Pol II-DSIF-PAF-SPT6
Seychelle M. Vos et al.
NATURE (2018)
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Hanghang Zhang et al.
CELL (2018)
Novel Targeting of Transcription and Metabolism in Glioblastoma
Yu-Ting Su et al.
CLINICAL CANCER RESEARCH (2018)
Transcription elongation factors represent in vivo cancer dependencies in glioblastoma
Tyler E. Miller et al.
NATURE (2017)
EXTH-67. TG02, A BRAIN-PENETRANT MULTI-CDK INHIBITOR, POTENTLY SUPPRESSES MYC-DRIVEN GLIOBLASTOMA
Jonathan Tsang et al.
NEURO-ONCOLOGY (2017)
CDK9 is a prognostic marker and therapeutic target in pancreatic cancer
Anna-Laura Kretz et al.
TUMOR BIOLOGY (2017)
BRCA1 recruitment to damaged DNA sites is dependent on CDK9
Thales C. Nepomuceno et al.
CELL CYCLE (2017)
Transcriptional Addiction in Cancer
James E. Bradner et al.
CELL (2017)
Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis
Xiangrong Liu et al.
TUMOR BIOLOGY (2016)
Overview of CDK9 as a target in cancer research
Fatima Morales et al.
CELL CYCLE (2016)
RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation
Qi Xie et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype
Feimeng Zheng et al.
NATURE COMMUNICATIONS (2016)
BRCA1-regulated RRM2 expression protects glioblastoma cells from endogenous replication stress and promotes tumorigenicity
Rikke D. Rasmussen et al.
NATURE COMMUNICATIONS (2016)
Inhibition of CDK9 as a therapeutic strategy for inflammatory arthritis
Annelie Hellvard et al.
SCIENTIFIC REPORTS (2016)
Toward precision medicine in glioblastoma: the promise and the challenges
Michael D. Prados et al.
NEURO-ONCOLOGY (2015)
The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation
Chiara Pastori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors
Diane A. J. van der Biessen et al.
CLINICAL CANCER RESEARCH (2014)
CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma
Chun-Hao Huang et al.
GENES & DEVELOPMENT (2014)
Brd4 and JMJD6-Associated Anti-Pause Enhancers in Regulation of Transcriptional Pause Release
Wen Liu et al.
CELL (2013)
The good, the bad and the ugly: Epigenetic mechanisms' in glioblastoma
Helena Caren et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties
K. C. Goh et al.
LEUKEMIA (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
A role for cdk9-cyclin k in maintaining genome integrity
David S. Yu et al.
CELL CYCLE (2011)
Overcoming anoikis - pathways to anchorage-independent growth in cancer
Marta C. Guadamillas et al.
JOURNAL OF CELL SCIENCE (2011)
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Weiwei Yang et al.
NATURE (2011)
Developmental profile and regulation of the glycolytic enzyme hexokinase 2 in normal brain and glioblastoma multiforme
Amparo Wolf et al.
NEUROBIOLOGY OF DISEASE (2011)
55K isoform of CDK9 associates with Ku70 and is involved in DNA repair
Hongbing Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Notch Promotes Radioresistance of Glioma Stem Cells
Jialiang Wang et al.
STEM CELLS (2010)
A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours
Edwina N. Scott et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases
Gaetano Romano et al.
CELL CYCLE (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Epigenetic aberrations in malignant gliomas - An open door leading to better understanding and treatment
Ramon Martinez et al.
EPIGENETICS (2007)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
分享论文
